Retrospective Analysis of the Correlation of MSI-H/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience
Authors:
- Valentina TuninettiValentina Tuninetti
- Luca PaceLPLuca Pace
- Eleonora GhisoniEGEleonora Ghisoni
- Virginia QuaràVQVirginia Quarà
- Francesca ArezzoFrancesca Arezzo
- Andrea PalicelliAndrea Palicelli
- Vincenzo Dario MandatoVMVincenzo Dario Mandato
- Elena GeunaEGElena Geuna
- Gennaro CormioGCGennaro Cormio
- Nicoletta BigliaNBNicoletta Biglia
- Lucia BorsottiLBLucia Borsotti
- Silvia GalloSGSilvia Gallo
Preprint
- 13 June 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: There is poor evidence about sensitivity to chemotherapy according to microsatellite instability (MSI)/mismatch repair (MMR) status in endometrial cancer (EC). Methodology: The RAME study is a retrospective analysis aiming to assess response to chemotherapy in MSI-high (h) /deficient (d) MMR and MSI- low (l)/proficient (p)MMR EC patients. Primary endpoints were recurrence-free survival (RFS) for patients with localized disease and progression-free survival (PFS) and overall survival (OS) in patients with advanced/recurrent disease. Results: 312 patients treated between 2010-2022 in 4 high volume Multicenter Italian Trial in Ovarian cancer and gynecological malignancies (MITO) centers were selected. 239 patients had endometrioid EC (76.6%), 151 had FIGO stage I at diagnosis (48.9%) and 71 were MSI-h/dMMR (22.8%). Median age was 65 (range 31–91) years. Among patients with localized disease, median RFS was 100.0 months (95%CI 59.4–140.7) for MSI-l/pMMR and 120.9 months (60.0-181.8) for MSI-h/dMMR (p=0.39). Seventy-seven patients received first-line chemotherapy for advanced/recurrent disease. Patients with MSI-h/dMMR ECs had a significantly worse OS (p=0.039). In patients receiving platinum-based chemotherapy, no statistically significant difference in PFS (p=0.21) and OS (p=0.057) were detected, although PFS and OS were numerically longer in the MSI-l/pMMR population. Conclusion: Patients with metastatic MSI-h/dMMR EC receiving first-line chemotherapy had a significantly worse OS.Keywords
All Related Versions
- Version 1, 2023-06-13, Preprints
- Published version: Cancers, 15 (14), 3639.
This publication has 26 references indexed in Scilit:
- Lenvatinib plus Pembrolizumab for Advanced Endometrial CancerNew England Journal of Medicine, 2022
- Endometrial cancerNature Reviews Disease Primers, 2021
- Endometrial cancer in Lynch syndromeInternational Journal of Cancer, 2021
- Endometrial Cancer: An Overview of Pathophysiology, Management, and CareSeminars in Oncology Nursing, 2019
- Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialThe Lancet Oncology, 2018
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1JAMA Oncology, 2015
- A clinically applicable molecular-based classification for endometrial cancersBritish Journal of Cancer, 2015
- Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiativeLaboratory Investigation, 2015
- Carboplatin and paclitaxel in advanced or metastatic endometrial cancerGynecologic Oncology, 2008
- Two pathogenetic types of endometrial carcinomaGynecologic Oncology, 1983